MRNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Moderna Inc (MRNA) is not a good buy for a beginner investor with a long-term strategy at this moment. The stock is currently in a pre-market decline (-0.15%) with significant insider and hedge fund selling activity. While there are some positive catalysts, such as the FDA's decision to review its flu vaccine and a raised price target by Piper Sandler, the company's financial performance is severely declining, and analysts remain mixed to negative on the stock. Additionally, technical indicators suggest the stock is overbought, and no strong proprietary trading signals are present today.
The MACD is positive at 0.602 and contracting, indicating a bullish trend. RSI is at 86.326, signaling overbought conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are R1: 52.631 and R2: 56.218, while support levels are S1: 41.018 and S2: 37.431.
FDA reversed its decision and will review Moderna's flu vaccine candidate, with potential approval by August
Piper Sandler raised the price target to $69, reflecting confidence in future growth.
Moderna plans to diversify its product portfolio to drive future growth.
Hedge funds and insiders are heavily selling the stock, with insider selling increasing by 89355.59% in the last month.
Revenue dropped significantly (-96.69% YoY) in Q4 2025, with a net income loss of $826M and gross margin at -1312.5%.
Analysts remain mixed to negative, with multiple underperform and neutral ratings.
In Q4 2025, revenue dropped to $32M (-96.69% YoY), net income fell to -$826M (-26.25% YoY), EPS declined to -2.11 (-26.99% YoY), and gross margin plummeted to -1312.5% (-3118.63% YoY). The company is facing severe financial challenges.
Analysts are mixed to negative on Moderna. Piper Sandler raised the price target to $69 with an Overweight rating, but BofA, Bernstein, and others maintain underperform or neutral ratings. Price targets range from $24 to $69, with skepticism about the company's ability to recover in the near term.
